FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance

FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance

Lung cancer has high morbidity and mortality rates worldwide, and NSCLC accounts for 85% of all lung cancer cases. Despite the development of targeted therapies and immunotherapy, many NSCLC patients do not effectively respond to treatment, and new treatment strategies are urgently needed. Aberrant...

Full description

Bibliographic Details
Main Authors: Feng Ma, Xinhai Zhu, Yuchun Niu, Aitao Nai, Shoaib Bashir, Yan Xiong, Yunlong Dong, Yin Li, Jian Song, Meng Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
FGFR inhibitor
AZD4547
nab-paclitaxel
MAPK signaling pathway
NSCLC
drug sensitivity
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1088444/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1088444/full

Similar Items